AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...
Dana-Farber Cancer Institute researchers are leading three studies that yield new insights to help improve treatment for patients with acute myelogenous leukemia (AML). The research teams will present ...